{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:35:13Z","timestamp":1783402513714,"version":"3.54.6"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.seizure.2019.12.024","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T13:09:07Z","timestamp":1577106547000},"page":"82-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"special_numbering":"C","title":["The efficacy of perampanel in young children with drug-resistant epilepsy"],"prefix":"10.1016","volume":"75","author":[{"given":"Fu-Man","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pi-Chaun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chin","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Hao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang-Tso","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.seizure.2019.12.024_bib0005","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1684\/epd.2015.0736","article-title":"Incidence, prevalence and aetiology of seizures and epilepsy in children","volume":"17","author":"Camfield","year":"2015","journal-title":"Epileptic Disord"},{"issue":"7","key":"10.1016\/j.seizure.2019.12.024_bib0010","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/j.1528-1167.2010.02546.x","article-title":"Course and outcome of childhood epilepsy: a 15\u2010year follow\u2010up of the Dutch Study of Epilepsy in Childhood","volume":"51","author":"Geerts","year":"2010","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.seizure.2019.12.024_bib0015","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s12098-014-1533-1","article-title":"Refractory epilepsy in children","volume":"81","author":"Aneja","year":"2014","journal-title":"Indian J Pediatr"},{"issue":"8","key":"10.1016\/j.seizure.2019.12.024_bib0020","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022863","article-title":"Glutamatergic mechanisms associated with seizures and epilepsy","volume":"5","author":"Barker-Haliski","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.seizure.2019.12.024_bib0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ane.12100","article-title":"Preclinical pharmacology of perampanel, a selective non\u2010competitive AMPA receptor antagonist","volume":"127","author":"Rogawski","year":"2013","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"10.1016\/j.seizure.2019.12.024_bib0030","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13052-017-0368-6","article-title":"Current role of perampanel in pediatric epilepsy","volume":"43","author":"De Liso","year":"2017","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.seizure.2019.12.024_bib0035","unstructured":"Biro A, Stephani U, Tarallo T, Bast T, Schlachter K, Fleger M, et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences. (1439-1899 (Electronic))."},{"issue":"9","key":"10.1016\/j.seizure.2019.12.024_bib0040","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1177\/0883073817709195","article-title":"Clinical experience with perampanel for refractory pediatric epilepsy in one Canadian center","volume":"32","author":"Datta","year":"2017","journal-title":"J Child Neurol"},{"issue":"5","key":"10.1016\/j.seizure.2019.12.024_bib0045","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1177\/0883073819827407","article-title":"Adjunctive perampanel oral suspension in pediatric patients from\u2265 2 to< 12 years of age with epilepsy: pharmacokinetics, safety, tolerability, and efficacy","volume":"34","author":"Renfroe","year":"2019","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2019.12.024_bib0050","article-title":"Efficacy and tolerability of adjunctive perampanel treatment in children under 12 years of age with refractory epilepsy","author":"Yun","year":"2018","journal-title":"J Korean Pediatric Society"},{"key":"10.1016\/j.seizure.2019.12.024_bib0055","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.yebeh.2018.06.033","article-title":"Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: the first real-world evaluation in Asian pediatric neurology clinics","volume":"85","author":"Lin","year":"2018","journal-title":"Epilepsy Behav"},{"issue":"9","key":"10.1016\/j.seizure.2019.12.024_bib0060","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1177\/08830738040190090801","article-title":"Managing epilepsy in tuberous sclerosis complex","volume":"19","author":"Thiele","year":"2004","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2019.12.024_bib0065","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eplepsyres.2016.08.021","article-title":"Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies\u2014an Italian observational multicenter study","volume":"127","author":"De Liso","year":"2016","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2019.12.024_bib0070","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jns.2018.04.017","article-title":"Perampanel as adjunctive therapy in highly refractory epilepsies: real-world data from an Italian tertiary care epilepsy centre","volume":"390","author":"Morano","year":"2018","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.seizure.2019.12.024_bib0075","unstructured":"Zhao JP, Yoshii AA-OX. Hyperexcitability of the local cortical circuit in mouse models of tuberous sclerosis complex. (1756-6606 (Electronic))."},{"key":"10.1016\/j.seizure.2019.12.024_bib0080","unstructured":"Wang Y, Greenwood Js Fau - Calcagnotto ME, Calcagnotto Me Fau - Kirsch HE, Kirsch He Fau - Barbaro NM, Barbaro Nm Fau - Baraban SC et al. Neocortical hyperexcitability in a human case of tuberous sclerosis complex and mice lacking neuronal expression of TSC1. (0364-5134 (Print))."},{"issue":"10056","key":"10.1016\/j.seizure.2019.12.024_bib0085","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2019.12.024_bib0090","unstructured":"Samueli S, Dressler AA-O, Groppel G, Scholl T, Feucht M. Everolimus in infants with tuberous sclerosis complex-related West syndrome: First results from a single-center prospective observational study. (1528-1167 (Electronic))."},{"issue":"4","key":"10.1016\/j.seizure.2019.12.024_bib0095","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.biopsych.2007.05.028","article-title":"Cellular mechanisms underlying the antidepressant effects of ketamine: role of \u03b1-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors","volume":"63","author":"Maeng","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.seizure.2019.12.024_bib0100","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3389\/fnbeh.2015.00162","article-title":"AMPA receptor\u2013mTOR activation is required for the antidepressant-like effects of sarcosine during the forced swim test in rats: insertion of AMPA receptor may play a role","volume":"9","author":"Chen","year":"2015","journal-title":"Front Behav Neurosci"},{"key":"10.1016\/j.seizure.2019.12.024_bib0105","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.seizure.2017.08.014","article-title":"Effectiveness and tolerability of Perampanel in children, adolescents and young adults with refractory epilepsy: a UK national multicentre study","volume":"52","author":"Swiderska","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2019.12.024_bib0110","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eplepsyres.2019.02.014","article-title":"Efficacy and tolerability of perampanel in pediatric patients with Dravet syndrome","volume":"154","author":"Yoshitomi","year":"2019","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2019.12.024_bib0115","doi-asserted-by":"crossref","DOI":"10.1111\/dmcn.14152","article-title":"Gene mutations in paediatric epilepsies cause NMDA\u2010pathy, and phasic and tonic GABA\u2010pathy","author":"Gataullina","year":"2019","journal-title":"Dev Med Child Neurol"},{"issue":"3","key":"10.1016\/j.seizure.2019.12.024_bib0120","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.yebeh.2011.11.022","article-title":"SCN1A mutations in Dravet syndrome: impact of interneuron dysfunction on neural networks and cognitive outcome","volume":"23","author":"Bender","year":"2012","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2019.12.024_bib0125","first-page":"947","article-title":"AMPA receptors in epilepsy and as targets for antiepileptic drugs","volume":"79","author":"Rogawski","year":"1999","journal-title":"Advances in Neurology-New York-Raven Press-"},{"issue":"4","key":"10.1016\/j.seizure.2019.12.024_bib0130","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ejpn.2015.02.008","article-title":"Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study","volume":"19","author":"Rosenfeld","year":"2015","journal-title":"Eur J Paediatr Neurol"},{"issue":"4","key":"10.1016\/j.seizure.2019.12.024_bib0135","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/dmcn.13362","article-title":"Tolerability and efficacy of perampanel in children with refractory epilepsy","volume":"59","author":"Heyman","year":"2017","journal-title":"Dev Med Child Neurol"},{"issue":"9","key":"10.1016\/j.seizure.2019.12.024_bib0140","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.jpsychires.2013.05.001","article-title":"Cerebrospinal fluid glutamate concentration correlates with impulsive aggression in human subjects","volume":"47","author":"Coccaro","year":"2013","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.seizure.2019.12.024_bib0145","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2064027","article-title":"Mechanisms underlying aggressive behavior induced by antiepileptic drugs: focus on topiramate, levetiracetam, and perampanel","volume":"2018","author":"Hansen","year":"2018","journal-title":"Behav Neurol"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131119304431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131119304431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:53:59Z","timestamp":1761011639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131119304431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":29,"alternative-id":["S1059131119304431"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2019.12.024","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy of perampanel in young children with drug-resistant epilepsy","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2019.12.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}